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Natural Antioxidants for the Prevention of Atherosclerosis 
Rudina M. Odeh, Pharm.D., and Laura A. Cornish, Pharm.D. 
Hypercholesterolemia, cigarette smoking, hypertension, and obesity are 
known contributing risk factors for the development of atherosclerotic 
coronary artery disease (CAD). However, they account for only half of all 
cases of CAD, and the complete pathologic process underlying atherosclerosis 
remains unknown. Growing evidence suggests that oxidative modification of 
low-density lipoprotein (LDL) may be of particular importance in the 
pathogenesis. Oxidized LDL exhibits proatherogenic effects. Therefore, 
current research has focused on inhibiting the oxidation of LDL as a means of 
inhibiting the atherosclerotic process. One such approach is to enhance the 
endogenous antioxidant defense systems within the LDL particle with 
lipophilic antioxidants such as a-tocopherol and p-carotene, or by 
supplementing the aqueous-phase antioxidant capacity with asqorbic acid. 
Observational data suggest a protective effect of antioxidant supplementation 
on the incidence of CAD; however, specific doses cannot be recommended 
since the data are inconclusive. 
(Pharmacotherapy 1995; 15( 5): 648-659) 
OUTLINE 
Hypothesis of Oxidative Modification 
Vitamin E 
p-Carotene 
Vitamin C 
Selenium 
Recommendations and Conclusions 
Acute myocardial infarction is a leading 
contributor to premature death among adults in 
Western civilization.', ' Its incidence in the 
United States has been estimated at  1.5 million 
cases annually (1: 160 persons), with more than 
500,000 deaths and approximately 750,000 
hospitalizations a An estimated 1.25 
million people experienced a myocardial 
infarction in  1993, and nearly 500,000 are 
thought to have died.2 
It is well known that the primary underlying 
cause of acute myocardial infarction is 
atherosclerotic coronary artery disease (CAD). 
Approximately 5.4 million individuals are 
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diagnosed with CAD annually, which collectively 
results in direct health care costs exceeding $8 
billion each year.6 However, the incidence of 
death due to CAD has declined substantially over 
the past 25 years.6 This decline may be 
attributed partly to a reduction of risk factors 
such as cigarette smoking, hypertension, obesity, 
and hypercholesterolemia. These factors account 
for nearly half of all cases of CAD, but the 
complete pathologic process underlying 
atherosclerosis remains unknown.' 
Scientific evidence strongly suggests that 
oxidative modification of the low-density 
lipoprotein (LDL) particle may play an important 
causative role in the development of 
atherosclerosis.' This theory, known as the 
oxidative modification hypothesis, has led to the 
development of many clinical and epidemiologic 
trials to examine the effect of various natural 
antioxidants (vitamin E, p-carotene, vitamin C, 
selenium) on the disease. 
Hypothesis of Oxidative Modification 
In vitro studies show that native (unmodified) 
LDL is unlikely to contribute to the development 
of atherosclerotic lesions. The lipoprotein may 
be transformed into an atherogenic agent 
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through several mechanisms,  including 
acetylation,’ nonenzymatic glycation,I0 and 
oxidation.” Evidence suggests that the oxidative 
modification of LDL may be of particular 
importance.’, l3  
Figure 1 outlines the oxidative modification 
hypothesis  a n d  depicts  the potent ia l  
proatherogenic effects of oxidized LDL.’+ The 
initial event is the accumulation of cholesterol- 
loaded foam cells within the subendothelial space 
of the arteries. These foam cells originate from 
monocyte-derived tissue macrophages, which 
internalize extracellular lipids such as LDL. 
Once formed, foam cells have the potential to 
accumulate within the subendothelial space to 
form a fatty streak. The fatty streak is the earliest 
manifestation of the atherosclerotic lesion.’5, l6 It 
can develop during childhood (first 2 decades of 
life), but during this period it is usually clinically 
silent. As the foam cells continue to accumulate, 
usually during the third and fourth decades, the 
fatty streak increases in size to form an overt 
atherosclerotic plaque.” 
The classic LDL receptor (apoprotein 
B/apoprotein E receptor) is expressed on the 
tissue macrophage and mediates the uptake of 
native LDL. However, the native LDL receptor is 
subject  to feedback inhibi t ion by cellular 
cholesterol content. The amount of native LDL 
taken up by the classic LDL receptor pathway is 
ARTERY WALL 
Figure 1. A schematic outline of the oxidative modification hypothesis, showing the several ways in which oxidized low- 
density lipoprotein (LDL) is potentially more atherogenic than native LDL. Monocytes, the major precursor for foam cells in 
the fatty streak, are shown adhering to the endothelium and then penetrating to the subendothelial space. Oxidized LDL can 
directly stimulate this by virtue of its lysolecithin content, and lightly oxidized LDL (MM-LDL) can stimulate indirectly by 
increasing the release of MCP-1 from endothelial cells. Oxidized LDL is a ligand for the scavenger receptor that is expressed as 
the monocyte differentiates to a tissue macrophage, and this leads to the accumulation of lipids in the developing foam cells. 
This monocytdmacrophage differentiation can be facilitated by the release of macrophage colony-stimulating factor (M-CSF) 
from endothelial cells under the influence of MM-LDL. Finally, oxidized LDL can induce endothelial damage and thus 
facilitate the atherogenic process by allowing entry of elements from the blood and by allowing adherence of platelets. 
Additional properties of oxidized LDL not shown here that may make it more atherogenic are the fact it is immunogenic and 
the fact that it interferes with response of arteries to endothelial-derived relaxation factor. Adapted from reference 14 with 
permission. 
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insufficient to generate lipid-laden foam cells.18 
In addition to the native LDL receptor, the 
macrophage expresses a second receptor known 
as the scavenger receptor. The scavenger 
receptor has a high affinity for modified forms of 
LDL such as acetylated and oxidized LDL, but 
not for native LDL.19 Uptake of the modified 
forms, primarily oxidized LDL, by the scavenger 
receptor is not limited by feedback inhibition. 
Thus, the inability of the scavenger receptor to 
down-regulate with the accumulation of 
cholesterol provides a mechanism for the 
continuous uptake of oxidized LDL and 
subsequent foam cell formation. This is believed 
to be the most significant route for the 
development of atherosclerotic lesions by 
oxidized LDL.20-24 
Once the LDL has been oxidized it has several 
proatherogenic effects. For example, it directly 
stimulates the monocyte to penetrate into the 
subendothelial space of the arterial wall where it 
may undergo transformation into a macrophage 
(foam cell precursor) .* Oxidized LDL inhibits 
the migration of macrophages, causing them to 
be retained within the arterial wall.25 It also is 
cytotoxic to endothelial and smooth muscle 
cells.24 Mildly oxidized LDL may indirectly 
attract monocytes into the arterial wall by 
stimulating the release of monocyte 
chemoattractant protein-1 (MCP-1) from 
endothelial cells.26, 27 In addition, the 
macrophage colony-stimulating factor (M-CSF) 
from endothelial cells facilitates the 
differentiation of monocytes to the tissue 
macrophage.26 Another potential atherogenic 
property of oxidized LDL is its ability to alter the 
response to endo thelium-derived relaxing factor 
(EDRF), thus potentially inhibiting arterial 
relaxation. 28 
Evidence linking oxidative modification of 
LDL with the development of cholesterol-laden 
foam cells and the subsequent formation of the 
fatty streak prompted clinicians to study the 
effects of various antioxidants on atheroma 
formation. The earliest studies, done in animals, 
were conducted with probucol, a lipid-lowering 
agent with antioxidant properties. These studies 
indicated that probucol slowed the progression of 
atherosclerosis by a mechanism independent of 
its hypocholesterolemic  effect^.^^-^^ The drug 
may also result in many unwanted adverse 
effects, such as a reduction in the level of high- 
density l ip~pro te in .~~,  34 Thus, a lot of attention 
has been focused on treatment with natural 
antioxidants. 
Enhancing the endogenous antioxidant defense 
systems within the LDL particle decreases 
oxidation of LDL and slows the atherogenic 
process without producing undesirable effects.35 
The endogenous defense system may be 
enhanced by micronu trient supplementation 
with lipophilic antioxidants such as a-tocopherol 
and p-carotene, or by supplementing the aqueous 
phase antioxidant capacity with ascorbic 
Many of the data supporting such supple- 
mentation were derived from prospective cohort 
studies that evaluated the effects of dietary intake 
and plasma concentrations of vitamin E, vitamin 
C, 6-carotene, and selenium on the occurrence of 
CAD. 
Vitamin E 
Each LDL particle contains within it various 
lipophilic antioxidants, including a-tocopherol, 
p-carotene, a-carotene, lycopene, ubiquinol-10, 
y-tocopherol, cryptoxanthin, cantaxanthin, and 
phy t~ f luene .~~  They all prevent oxidation of the 
polyunsaturated fatty acids (PUFAs) bound to 
LDL, including linoleic acid, arachidonic acid, 
and docosahexanoic acid. The largest and most 
prominent of the antioxidants is a-tocopherol, 
the main component of vitamin E. Each LDL 
particle contains approximately 6 molecules of a- 
tocopherol; the remaining antioxidants in LDL 
account for 1/20th to 1/300th of that amount.36 
Vitamin E plays a pivotal role in protecting 
LDL from lipid peroxidation. For example, 
heavy oxidative modification of LDL will not 
occur unless endogenous vitamin E is de~leted.~’? 
3 7 9 3 8  Vitamin E competes for peroxyl radicals at a 
faster rate than PUFAs. Therefore, even minute 
amounts of vitamin E can effectively protect a 
large number of PUFAs from oxidation.39 Since 
the correlation between oxidation and vitamin E 
is concentration dependent, the delay in  
oxidation of LDL can be increased by raising the 
plasma concentration of vitamin E with dietary 
s~pplementation.~~, 41 
Epidemiologic Studies 
Plasma Concentrations 
Cross-cultural epidemiologic studies conducted 
in Europe showed a strong inverse correlation 
between plasma vitamin E concentration and 
CAD.42, 43 During the World Health Organization/ 
Multinational Monitoring of Trends and 
Determinants in  Cardiovascular Disease 
(WHO/MONICA) project, cardiovascular risk 
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assessments and blood samples were taken on 
groups of approximately 100 healthy men age 
40-49 years, from regions with different rates of 
CAD mortality. Plasma levels of essential 
antioxidants (vitamin E, p-carotene, vitamin C, 
selenium) were inversely correlated with cross- 
cultural  CAD mortality in  16 European 
populations. The results of this study revealed 
only a weak direct correlation between the 
incidence of CAD and the two classic risk factors, 
total plasma cholesterol (r2=0.29, p=0.03) and 
blood pressure (diastolic r2=0.25, p=0.05; systolic 
r2=0.19, p=0.09). In addition, 12 of the 16 study 
populations had what was considered to be 
normal total plasma cholesterol levels of 5.7 to 
6.2 mmoVL (220-240 mg/dl). In this subgroup, 
total plasma cholesterol (r2=0.04, p=0.53) and 
blood pressure (diastolic r2=0.08, p=0.36; systolic 
r2=0.01, p=0.80) did not have a significant 
correlation with CAD mortality. 
Among all populations evaluated, however, 
vitamins E and A had an inverse correlation with 
CAD mortality, strongest with vitamin E. The 
correlation coefficient was significant for lipid- 
standardized levels and absolute levels in the 
subgroup of populations with normal cholesterol 
(r2=0.73, p=0.0004 and  r2=0.63, p=0.002,  
respectively). The correlation coefficient was 
also highly significant for lipid-standardized 
vitamin E levels for all populations (r2=0.62, 
p=0.0003). Thus, as found in this study, the risk 
of CAD mortality may relate more significantly to 
low vitamin E levels than to traditional risk 
factors such as high total cholesterol levels and 
high blood pressure. 
Dietary Intake 
The Scottish Heart Health Study was 
conducted to determine the relationship between 
diet and the risk of CAD in a cross section of 
10,359 men and women age 40-59 years, 
selected from patients of general practitioners 
throughout Scotland.44, 45 The subjects 
completed questionnaires to provide information 
on food intake, sociodemographics, and health 
knowledge, as well as a separate one on chest 
pain. Based on this information, they were 
divided into three categories: the control group 
(73.3%, 3828 men and 3790 women), a group 
with diagnosed CAD (6%, 385 men and 240 
women),  and one with undiagnosed CAD 
(14.5%, 684 men and 813 women). A total of 
619 subjects were excluded before classification. 
The authors reported a significant reduction in 
the risk of having undiagnosed CAD among men 
in the highest quintile of dietary vitamin E intake 
(p<0.05). However, this trend was not evident 
among women with diagnosed and undiagnosed 
CAD in the highest quintile of vitamin E intake 
compared with those in the lowest quintile. 
The correlation between vitamin E intake and 
the incidence of heart disease was investigated 
in  the Nurses’ Health Detailed 
questionnaires were completed by 87,245 
registered nurses, all women, regarding their 
dietary intake, lifestyle, and medical history. 
Subsequent questionnaires were sent every 2 
years for follow-up on newly diagnosed illnesses, 
information on dietary and supplemental vitamin 
E intake, and multivitamin supplementation. 
The follow-up was carried out over 8 years and 
was 97% complete. 
An inverse correlation was observed between 
vitamin E intake and CAD. After adjusting for 
other nutrients and coronary risk factors, the 
relative risk for major coronary disease (defined 
as nonfatal myocardial infarction or death due to 
coronary disease) among women in the highest 
quintile of total vitamin E intake, including 
supplements, compared with women in the 
lowest was 0.66 (p<O.OOl), which corresponds to 
a 34% reduction in  risk for major coronary 
events. N o  apparent association was seen 
between dietary intake of vitamin E without 
supplements and the relative risk for major 
coronary disease as defined above (relative risk 
0.95, p=0.99). 
The reduction in the risk of coronary disease 
was attributable to the intake of vitamin E from 
supplements rather than from the diet. Doses 
less than 100 IU/day were not of significant 
benefit in reducing the risk (relative risk 0.93), 
and no dose-response association was apparent 
when the dose was increased above 100 IU/day. 
The relative risk was 0.56 for doses of 100-250 
IU/day, 0.56 for 300-500 IU/day, and 0.58 for 
greater than 600 IU/day. Overall, a 40% 
reduction in the risk of coronary disease was 
observed among middle-aged women who took 
vitamin E supplements compared with women 
who did not take supplements. 
Similar results were observed in the Health 
Professionals Follow-up Study, a large, 
prospective study of 39,910 men health 
professionals between the ages of 40 and 75 
years.47 All subjects completed a detailed 
questionnaire to assess diet and medical history. 
Follow-up questionnaires were sent biannually 
during the 4-year study. As in the Nurses’ Health 
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Study, an inverse correlation between vitamin E 
intake and relative risk of coronary disease was 
observed. The men in the highest quintile of 
vitamin E intake had a 41% reduction in the age- 
adjusted relative risk of coronary disease (relative 
risk 0.59, p=O.OOl) compared with those in the 
lowest quintile of intake. The greatest reduction 
was in men taking daily doses of 100-249 1U. 
The relative risk did not decrease further when 
higher doses were taken. Duration of vitamin E 
use and risk of coronary disease were also 
inversely related. 
Compared with nonusers of vitamin E, men 
who claimed to have taken vitamin E 
supplements for 10 or more years had an 
unadjusted relative risk of 0.65. Those who 
reported taking multivitamins for 10 or more 
years had an unadjusted relative risk of 0.75 
compared with nonusers. Thus, vitamin E 
supplements were of greater benefit in reducing 
the risk of coronary disease than multivitamins. 
Finally, an assessment of overall mortality 
revealed a 22% decrease in risk among men in 
the highest quinti le of vitamin E intake,  
compared with those in the lowest quintile 
(relative risk 0.78, p=0.06). Similar to the 
findings with nurses, vitamin E supplements 
were strongly associated with a significant 
reduction in the risk of coronary heart disease. 
The same association was not observed among 
individuals receiving vitamin E solely through 
dietary intake or multivitamins. 
Not all trials evaluating the effects of vitamin E 
on CAD risk reported positive results. In fact, 
some prospective cohort  studies failed to 
demonstrate an inverse correlation between the 
Three hundred ninety-five healthy men 
between ages 40 and 49 years were randomly 
selected from four regions in Europe (north 
Karelia, southwest Finland, Scotland, southern 
Italy) with different rates of CAD 51 
Of these four regions, north Karelia had the 
highest rate for these men, followed by southwest 
Finland, Scotland, and Italy. Vitamin E plasma 
concentrations were low among Scottish men 
(p<O.OO 1) but did not differ significantly among 
men in the other three regions. Thus, the studies 
failed to show a relationship between low vitamin 
E concentrations and cross-cultural differences in 
mortality from CAD. In this trial, the blood 
samples were subjected to deep freeze (-70°C) for 
prolonged periods of time, which may have 
resulted in a substantial loss of vitamin E. Since 
the vitamin’s stability under such conditions is 
unknown, the results from these studies may be 
flawed. 
In summary, most cross-cultural European 
cohorts indicate that vitamin E plasma 
concentrations are inversely correlated with CAD 
mortality. There is also convincing evidence that 
vitamin E supplements are associated with a 
significant decrease in the risk and possibly the 
incidence of CAD due to the vitamin’s 
antioxidant effects. 
Potential Adverse Effects 
Symptoms of vitamin E toxicity (hyper- 
vitaminosis E)  are fatigue, weakness, nausea, 
headache, blurred vision, flatulence, and 
diarrhea.52 They are generally transient and mild. 
In large studies, including well-controlled 
double-blind trials of oral vitamin E supple- 
mentation, doses as high as 3200 IU/day rarely 
induced adverse events.53 As oral intake exceeds 
100 IU/day, the rate of tissue accumulation 
decreases.54 Only 0.6% orf patients who received 
doses of 200-1000 IU/day for up to 11 years 
experienced adverse effects, including 
gastrointestinal symptoms, dermatitis, and 
fatigue.39 However, if the vitamin and oral 
anticoagulants are administered concomitantly, 
the risk of bleeding may be increased.52 
In patients with vitamin K deficiency 
secondary to malabsorption, high-dose vitamin E 
supplementation may exacerbate existing 
coagulation abnormalities. In patients without 
vitamin K deficiency, vitamin E has not been 
associated with coagulation abnormalit ie~.~~ 
Vitamin E has a safety factor well over 100 
times the recommended daily allowance.56 
Nevertheless, i t  can potentially accumulate in 
adipose tissue, so long-term self-treatment with 
large doses is not devoid of risk. 
A recent primary prevention trial, the Alpha- 
Tocopherol, Beta-Carotene (ATBC) Cancer 
Prevention Study, was conducted in 29,133 men 
smokers to determine whether supplementation 
with p-carotene 20 mg/day, vitamin E 50 mg/day, 
or both would reduce the incidence of lung 
cancer over a 5 -  to 8-year f ~ l l o w - u p . ~ ’  
Unfortunately, this study failed to show a 
beneficial effect of either agent. The change in 
the incidence of lung cancer among men who did 
as opposed to those who did not receive vitamin 
E was -2% (95% confidence interval -14-12%). 
This trial also unexpectedly revealed that among 
men who received a-tocopherol compared with 
those who did not, more deaths were caused by 
hemorrhagic stroke (7.8% and 5.2%, respectively) 
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or cancers other than lung cancer (34.7% and 
30.4%, respectively). However, there were fewer 
reported deaths due to ischemic heart disease and 
ischemic stroke among men receiving a- 
tocopherol than in those who did not receive the 
agent. Overall mortality was 2% greater in 
groups receiving a-tocopherol than in those not 
receiving a-tocopherol (95% CI -5-9%, p=0.6). 
@Carotene 
In vitro studies have shown that vitamin E is 
the first of the antioxidants in LDL to be 
consumed. Once the stores of vitamin E are 
depleted, consumption of the carotenoids (p- 
carotene, lycopene) ensues. Peroxidation of LDL 
does not occur until all of the carotenoids have 
been consumed. Thus, P-carotene and lycopene 
serve as a second line of defense against the 
oxidative modification of LDL.38, 40. 58 
p-Carotene is thought to inhibit  lipid 
peroxidation by trapping or deactivating singlet 
oxygen and free radicals.59 Experimental data 
indicate that its antioxidation activity may also 
play an important role in preventing athero- 
sclerosis. @-Carotene effectively inhibits copper- 
catalyzed oxidation of LDL.60 The in vitro 
antioxidant effect appears to correlate with the 
plasma concentration of p-carotene, since LDL 
containing the higher p-carotene level displayed 
a substantially greater resistance to oxidative 
modification. In addition, p-carotene successfully 
inhibits macrophage modification of LDL and the 
subsequent uptake and degradation of oxidized 
LDL by the macrophage scavenger r e~ep to r .~ '  
Thus, in vitro evidence strongly suggests that it 
has prominent antiatherogenic effects. 
Epidemiologic Studies 
Plasma Concentrations 
Of the 16 European populations evaluated 
during the WHO/MONICA project, 12 had 
normal cholesterol (220-240 mg/dl) and blood 
pressure. Statistical analysis of those 12  
populations revealed a weak inverse correlation 
between p-carotene plasma concentration and 
ischemic heart  disease mortality (r2=0.21, 
p=O. 14) .42, 43 
Dietary Intake 
Several prospective cohort  studies were 
conducted to determine if an inverse correlation 
exists between p-carotene intake and the risk of 
heart disease. The first and largest of these was 
the Nurses' Health Study. After adjustment for a 
variety of other coronary risk factors, the relative 
risk for CAD for women in the highest quintile of 
p-carotene intake compared with those in the 
lowest was 0.78 (95% CI 0.59-1.031, which 
corresponds to a 22% reduction in risk of CAD.".61 
A significant trend toward a reduction in the 
risk of CAD with increased p-carotene intake was 
also observed in the Health Professionals Follow- 
up The relative risk of CAD was 29% 
less among men with the highest 20% intake of 
p-carotene after adjusting for age and 
multivariate coronary risk factors (relative risk 
In the Scottish Heart Health Study the risk of 
having undiagnosed CAD was significantly lower 
in men within the highest quintile of p-carotene 
intake compared with those in the lowest. 
However, this trend was not observed among 
The association between dietary intake of p- 
carotene and the risk of cardiovascular disease 
(CVD) was recently investigated in a prospective 
cohort of 1299 elderly Massachusetts residents.62 
Baseline dietary information was gathered with a 
food frequency questionnaire during a face-to- 
face interview and was used to determine a p- 
carotene vegetable score for each subject, which 
corresponded with the number of servings of 
foods rich in p-carotene consumed per day. 
Follow-up information was collected by annual 
questionnaires mailed to each participant and an 
additional face-to-face interview. Over 4.75 years 
of follow-up, 161 deaths were due to CVD, of 
which 48 were attr ibuted to myocardial 
infarction. 
After adjusting for age and sex, the relative risk 
for CVD death among those in the highest 20% 
of p-carotene vegetable score was 0.54, compared 
with those in the lowest (p=0.004). For fatal 
myocardial infarction the relative risk was 0.25 
(p=0.0019) after adjusting for age and sex. Thus 
the trend toward decreased cardiovascular 
mortality with increased dietary p-carotene 
intake was statistically significant in this cohort. 
0.71, p=0.02). 
Clinical Trials 
The Physicians' Health Study, a randomized, 
placebo-controlled, intervention trial was 
initiated in 1982 to examine the effects of low- 
dose aspirin on mortality from CVD and to 
determine if p-carotene reduces the incidence of 
cancer.58' 63 The trial was a two-by-two factorial 
design involving over 22,000 men physicians in 
654 PHARMACOTHERAPY Volume 15, Number 5,1995 
the United States between ages 40 and 84 years. 
The subjects were randomized to one of four 
treatment groups: aspirin 325 mg and placebo 
on alternate days; aspirin 325 mg and 6-carotene 
50 mg on alternate days; p-carotene 50 mg and 
placebo on alternate days; and only placebo on 
all days. 
Before randomization, a subgroup of 333 
subjects was found to have a history of angina 
pectoris or coronary revascularization. Analysis 
of these subjects revealed that after adjusting for 
age and aspirin assignment, men receiving p- 
carotene 50 mg on alternate days had a 44% 
reduction in all major cardiovascular events, 
including myocardial infarction, revascularization, 
and cardiac death, in comparison with placebo 
treatment (relative risk 0.56, p=0.046).  In 
addition, a significant reduction in all major 
vascular events of up to 49% was seen among 
those receiving p-carotene 50 mg on alternate 
days (adjusted relative risk 0.51, p=0.015). 
Controlling for other coronary risk factors did 
not significantly alter these results. Thus, the 
preliminary results from this study strongly 
suggest that p-carotene may play an important 
role in the primary prevention of cardiovascular 
disease. 
In summary, the results of these cohort trials 
provide convincing data supporting the theory 
that P-carotene may be beneficial in reducing the 
risk for and mortality from CAD. 
Potential Adverse Effects 
As the oral intake of p-carotene increases, a 
decline in intestinal absorption occurs, which 
ultimately reduces any risk for toxicity. Although 
p-carotene is a provitamin of vitamin A, the risk 
for vitamin A toxicity due to high intake of P- 
carotene is virtually nonexistent because as 
intake increases, conversion to vitamin A 
decreases.64 However, oral intake of p-carotene 
resulting in serum levels in excess of 0.4 mg/dl 
has been associated with carotenodermia, a 
reversible and benign yellowing of the 
Excessive doses have also been associated with 
occasional loose stools.  Ecchymoses and 
arthralgias are reported rarely.66 The safety of (3- 
carotene has been established in doses of 15-50 
m g / d a ~ ~ ~  The agent should be administered with 
caution to individuals with hepatic or renal 
dysfunction, since safety in  this patient 
population has not been e~tabl ished.~~ 
Men receiving p-carotene supplementation had 
an increased incidence of lung cancer over those 
who did not receive supplementation (change in 
incidence 18%, 95% CI 3-36°h).57 Mortality rates 
between the groups were greatest for lung cancer 
(35.6% and 30.8%, respectively), ischemic heart 
disease (77.1% and 68.9%), hemorrhagic stroke 
(7.0% and 6.0%), and ischemic stroke (8% and 
6.5%). Overall mortality was 8% higher among 
recipients of p-carotene than nonrecipients (95% 
CI 1-16%, p=0.02). 
Vitamin C 
Vitamin C is a water-soluble antioxidant that 
acts as the body's primary defense against peroxyl 
radicals formed in the aqueous phase. I t  is the 
only endogenous antioxidant in plasma capable 
of completely inhibiting oxidative modification 
of LDL by aqueous peroxyl radicals.68,69 
When oxygen free radicals were produced in 
the aqueous phase,  vitamin C was rapidly 
consumed, resulting in a delay of the induction 
phase of the free radica'l chain me~hanism.~ '  
Vitamin C was the first antioxidant to disappear, 
followed by slower elimination of vitamin E. The 
level of vitamin E did not decline until vitamin C 
was completely eliminated. 
Vitamin C suppresses LDL peroxidation by 
intercepting the aqueous radicals, producing a 
break in the chain propagation of the free radical 
chain mechanism. In in vitro studies it failed to 
suppress the oxidation of LDL when it was added 
after the stores of vitamin E had been exhausted, 
indicating that it is an effective and efficient 
weapon against aqueous radicals, with virtually 
no antioxidant activity against lipophilic peroxyl 
 radical^.^' 
Although the other aqueous antioxidants 
(bilirubin, urate, sulfhydryl groups) can scavenge 
only some of the free radicals, ascorbate 
effectively sequesters all the aqueous peroxyl 
radicals before they diffuse into the lipid phase. 
Once all the vitamin C has been consumed, any 
radicals that  pass into the lipid phase are 
scavenged by the primary lipophilic antioxidant 
vitamin E.69 The protective effect of vitamin C 
on vitamin E also is well documented. Vitamin C 
acts to regenerate vitamin E at the water-lipid 
interphase by reducing the tocopheroxyl radical 
back to the active tocopherol form.72, 73 
Epidemiologic Studies 
Plasma Concentration 
When the 1 2  European populations with 
normal cholesterol and blood pressure of the 
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WHO/MONICA project were examined, plasma 
vitamin C concentration showed a significant 
inverse correlation with the incidence of CAD 
(r2=0.41, ~ = 0 . 0 3 ) . ~ ~  However, when all 16 
populations were considered, the relationship 
was no longer significant (r2=0. 11, p=O.22). 
Dietary Intake 
The relationship between ascorbate intake and 
mortality was evaluated in 14,407 subjects 
between 25 and 74 years of age in a prospective 
cohort study, the First National Health and 
Nutrition Examination Study (NHANES).j4 
Extensive diet and nutr i t ion information, 
including vitamin supplementation use, was 
gathered between 1971 and 1974 by personal 
interviews, questionnaires, and food frequency 
surveys. A follow-up survey was subsequently 
conducted in 1982-1984 in which information 
was collected from 90% of the original 
participants. The final results are based on a 
population of 10,550 subjects. They were 
divided into three categories based on daily 
vitamin C intake (vitamin C index): 0-49 mg, 
SO+ mg without regular supplements, and 50+ 
mg with regular supplements. The standardized 
mortality ratio (SMR) was then determined for 
the subgroups that were defined by several 
variables, including age, sex, and vitamin C 
index. The SMR for each subgroup was 
calculated as the number of observed deaths 
divided by the number of expected deaths, 
expressed as a percentage. Thus, comparisons 
were made relative to all United States 
Caucasians for whom the SMR is defined to be 
1.00. The results showed that among those with 
the highest vitamin C intake (50+ mg and regular 
supplements), the SMR for all CVD, defined as 
codes 390 through 459 by the ninth revision of 
the International Classification of Diseases (ICD 
9) ,  was 0.58 (0.41-0.78) for men and 0.75 
(0.55-0.99) for women. An inverse correlation 
between SMR and vitamin C intake was strong 
for all CVD for men and weak for women. 
Results from the Scottish Heart Health Study 
revealed that, compared with men in the lowest 
quintile of vitamin C intake, men in the highest 
quintile were at a significantly lower risk for 
having undiagnosed CAD (p=0.05) .44, 45 This 
dose-response relationship did not hold true for 
women. 
Data in the Nurses' Health Study strongly 
suggested that increased intake of vitamin C may 
be associated with a decreased risk of CAD.46, j 5  
Among women in the highest quintile of vitamin 
C intake compared with those in the lowest, the 
relative risk was 0.65 (95% GI 0.49-0.86) after 
multivariate adjustment for other coronary risk 
factors.75 
Some cohort studies reported that an inverse 
association between vitamin C intake and the 
incidence of heart disease does not exist. For 
instance, in the Health Professionals Follow-up 
Study, among subjects in the highest quintile of 
vitamin C intake (median 1162 mg/day) 
compared with those in the lowest (median 92 
mg/day), the multivariate relative risk was 1.25 
(95% CI 0.91-1.71).47 A cross-sectional trial also 
failed to detect a specific relationship between 
plasma vitamin C concentrations and CAD.51 
In conclusion, vitamin C has a weak inverse 
correlation with the incidence and mortality of 
CAD, and this may not  be an independent 
relationship. Vitamin C may not be as promising 
in preventing CAD as vitamin E and p-carotene. 
Potential Adverse Effects 
Vitamin C is primarily eliminated by the 
kidneys, and evidence indicates that the renal 
threshold is attained at a plasma concentration of 
0.8-1.4 mg/dl. The vitamin appears in urine as 
the plasma concentration exceeds the renal 
t h r e ~ h o l d . ~ ~ - ~ '  In addition, as the dose is 
increased, absorption decreases. This dose- 
absorption relationship was substantiated in 
several clinical trials. At a dose of 30 mg, 95% of 
the drug is absorbed, however, with doses of 6 g 
and 12 g absorption decreases to 25% and 16%, 
respe~tively.~~, 'O 
Similar to the other antioxidants, the potential 
for a vitamin C overdose or toxicity is highly 
unlikely. However, large doses of 1-5 g/day may 
cause diarrhea, nausea, and vomiting.77 Large 
doses may also result in precipitation of oxalate, 
cysteine, or urate renal stones if the urine 
becomes acidic during therapy.*l Oxalate also 
accumulates in patients with chronic renal failure 
and those receiving long-term hemodialysis,82 
and these individuals should be cautioned 
against taking large doses of vitamin C. The 
vitamin is contraindicated in  patients with 
hemochromatosis and other conditions 
characterized by iron ~ v e r l o a d . ' ~  Maternal 
ingestion of doses in excess of 400 mg/day during 
pregnancy was associated with scorbutic 
conditions in infantsE4 Vitamin C dependency 
was documented in  adults consuming large 
quantities of a ~ c o r b a t e . ~ ~  
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Selenium 
Selenium is an essential trace element in humans. 
It is a necessary constituent of the selenoenzyme 
glutathione peroxydase (GSH-Px), an enzyme 
thought to act in the destruction of hydrogen 
peroxide and organic hydroperoxidess6* 87 
Selenium may be a vital component in protecting 
the coronary endothelium from oxidative 
damage. The dependence of GSH-Px activity on 
selenium prompted many investigators to study 
the possibility of an inverse relationship between 
cardiovascular disease and selenium concentration. 
An inverse correlation was seen between 
plasma selenium concentrations and the severity 
of coronary atherosclerosis as determined by 
arteriography,88 The absence of narrowing as 
great as 50% of any coronary arterial lumen was 
defined as “zero-vessel’’ disease. One-, two-, and 
three-vessel diseases were defined as a narrowing 
of 50% or more in the corresponding number of 
the three major coronary arteries or their 
branches. Of the 106 patients in this study, 15 
had zero-vessel disease (control group), 24 one- 
vessel, 19 two-vessel, and 33 three-vessel disease. 
The mean plasma selenium concentrations of the 
patients with two- (111.3 pg/L) and three-vessel 
disease (105.2 pgL) were significantly less than 
that of the control group (136.3 pg/L, ~ 1 0 . 0 5 ) .  
Selenium concentrations of patients with one- 
vessel disease (119.2 pg/L) did not  differ 
significantly from those in the control group. 
Thus, the total selenium concentration appeared 
to be inversely related to the severity of coronary 
atherosclerosis. The question remains as to 
whether a decrease in serum selenium concen- 
tration contributes to the development of 
atherosclerosis, is a result of atherosclerosis, or is 
simply a side effect of atherogenesis with no 
direct relevance to it. 
A prospective epidemiologic study conducted 
in  Finland revealed a l ink between serum 
selenium concentrations below 45 pg/L and an 
increased risk of CHD, cardiovascular disease, 
and myocardial infar~t ion.~’  In addition, the 
serum level was inversely associated with platelet 
aggregability and positively associated with 
plasma high-density lipoprotein choles te r~ l .~~  A 
significantly lower activity of GSH-Px in platelets 
was observed in patients who suffered an acute 
myocardial infar~tion.’~ A similar association 
was seen between serum selenium and the 
incidence of CHD and acute myocardial 
infar~tion.’~ The concentrations were significantly 
lower in patients with acute infarction and those 
with CAD ( ~ ~ 0 . 0 1 ) .  However, much of the 
information on selenium is controversial, and 
several studies failed to find a consistent 
association between serum selenium and the risk 
Based on epidemiologic findings, selenium may 
be of potential benefit in preventing CAD, but 
the data are inconsistent. Until it is studied in 
more detail, the true effects of selenium on heart 
disease will remain unknown. 
of CAD.43,48.49.93 
Potential Adverse Effects 
Toxicity is highly unlikely when selenium is 
taken at the recommended dosages, although 
excessive amounts can be Symptoms of 
selenium toxicosis include hair loss, weak nails, 
dermatitis, dental  defects, gastrointestinal 
disorders, nervousness, mental depression, 
metallic taste, vomiting, and garlic odor of breath 
and sweat. Acute selenium poisoning may result 
in death. The sequence of events preceding 
death usually consists of fulminant peripheral 
vascular collapse, internal vascular congestion, 
diffuse hemorrhea, pulmonary congestion and 
edema, and coma.94 Toxicity is usually confined 
to individuals living in seleniferous areas95 or 
those with long-term industrial exposure.96 
The intake required to elicit toxicity is 
unknown. However, doses of 100-600 pg/day 
have been associated with t o x i ~ i t y . ’ ~  The 
maximum recommended dietary intake for adults 
is 200 ~ g / d a y . ~ ~  
Recommendations and Conclusions 
Although it is speculative at this time, patients 
who may gain the most benefit from dietary 
supplements of antioxidants are those in high- 
risk groups, such as those with a history of 
angina pector i~,~’  coronary revasc~larization,~~ 
hyperlipidemia,42, 43 h y p e r t e n s i ~ n , ~ ~ ?  43 and 
myocardial infar~t ion.’~~ 92 Since smokers have 
decreased LDL ascorbate and P-carotene levels, 
and are especially prone to oxidative stress, they 
may also be good candidates for antioxidant 
therapy.99-101 
Most of the data reported in the literature are 
supportive of supplemental vitamin E to prevent 
CAD, but less supportive of p-carotene and 
vitamin C. Clearly, large-scale, placebo- 
controlled, comparative trials are warranted,lo2 
but until they are performed, the optimum 
antioxidant and dosage cannot be established. 
The literature regarding vitamin E indicates 
that the relative risk of developing coronary 
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disease in  middle-aged women was most 
significantly reduced in those who had a median 
intake of 208 1 U / d a ~ . ~ ~  Similarly, the greatest 
reduction in risk was observed in men taking 
100-249 IU/day4’ Doses greater than 400-800 
IU/day have not been associated with an increase 
in efficacy. 
Since p-carotene is essentially nontoxic, it may 
be given in “maximum non-yellowing doses.”’02 
Serum levels of p-carotene greater than 0.4 mg/dl 
were associated with a benign yellowing of the 
skin.65 Doses of 15-50 mg/day are established to 
be safe.67 
In prospective cohort studies, doses of vitamin 
C above 50 mg/day were associated with a 
reduced risk of coronary heart disease.45 Doses 
greater than 1 g/day do not significantly alter 
plasma concentrations of vitamin C.’03 
The recommended daily allowance for 
selenium is 70 pg/day for adult men and 55 
pg/day for adult women. These amounts will 
allow maximization of GSH-Px.lo4 The 
maximum recommended dietary intake of 
selenium is 200 pg/day9’ The average American 
adult consumes approximately 83-1 29 pg/day, 
and consequently, normal blood concentrations 
range from 58-234 pg/L (0.74-2.97 mmoVL) and 
normal serum levels range from 46-143 pg/L 
(0.58-1.82 m m ~ l / L ) . ” ~  In an epidemiologic 
study, a significant decrease in  coronary 
atherosclerosis was observed in subjects with 
plasma concentrations of 136.3 pg/L, compared 
with patients with total plasma selenium of 105.2 
pg/L (~10.01).~’ Patients in this study were not 
given supplemental selenium before the plasma 
was sampled. 
The recommendation of specific dosages of 
antioxidants to prevent atherosclerosis is 
premature since the issue remains controversial. 
Although most of the observational data strongly 
suggest a protective effect of antioxidant 
supplements on the incidence of CAD, they are 
inconclusive. In addition, long-term safety issues 
associated with supplemental doses of vitamin E, 
P-carotene, and vitamin C have not been 
resolved. It is important to note that sufficient 
amounts of p-carotene and vitamin C can be 
achieved through dietary intake. Thus, a daily 
multivitamin supplement may be appropriate for 
some patients, but should not be routine for all, 
especially those who consume a balanced diet. 
In contrast, i t  appears unlikely that sufficient 
quantities of vitamin E can be obtained from 
foods or even standard multivitamins. 
The Harvard Physicians’ Health Study is the 
only large-scale intervention trial that has 
reported preliminary results. This trial is 
continuing, and final results of the p-carotene 
arm should be made available in the near future. 
Other prospective primary prevention trials also 
are in progress, but until the results are available 
i t  may be prudent to avoid providing general 
recommendations regarding the use of 
antioxidants for preventing cardiovascular 
disease. 
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